|
Dr. Horwith is a board-certified internist with infectious disease and immunology sub-specialty training and is responsible for guiding clinical development of all Sequella pipeline product candidates. As a 22-year pharmaceutical industry veteran, Dr. Horwith has expertise in clinical evaluation, infectious disease, and registration of new drugs, and a proven track record of bringing investigational products from Phase I through NDA, BLA, and CTD filings. Prior to joining Sequella, Dr. Horwith was Vice President of Clinical Research and Medical Affairs at Nabi Biopharmaceuticals. Prior to Nabi, he was VP of Clinical Research and Drug Regulatory Affairs at Genetic Therapy, Inc., a Novartis company. He has served as Director of Worldwide Clinical Research at the Liposome Company in Princeton, NJ and Wyeth-Ayerst Research in Radnor, PA. Dr. Horwith completed his internal medicine residency training, and infectious disease fellowship at the University of Connecticut and UC-Irvine hospitals, respectively. Dr. Horwith has authored numerous publications in peer-reviewed journals. | 